HomepageTTNP • NASDAQ
add
Titan Pharmaceuticals, Inc. common stock
Vorige slotkoers
$Â 4,35
Dag-range
$Â 4,07 - $Â 4,55
Jaar-range
$Â 3,03 - $Â 14,80
Beurswaarde
5,81Â mln. USD
Gem. volume
32,42K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | — | — |
Bedrijfskosten | 534,00K | -49,76% |
Netto inkomsten | -563,00K | 46,89% |
Netto winstmarge | — | — |
Winst per aandeel | — | — |
EBITDA | -532,75K | 49,79% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 1,94Â mln. | -68,42% |
Totale activa | 2,16Â mln. | -67,56% |
Totale passiva | 279,00K | -50,09% |
Totaal aandelenvermogen | 1,88 mln. | — |
Uitstaande aandelen | 914,23K | — |
Koers-boekwaardeverhouding | 2,12 | — |
Rendement op activa | -52,57% | — |
Rendement op kapitaal | -61,85% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -563,00K | 46,89% |
Operationele kasstroom | -867,00K | -41,44% |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | -19,00K | — |
Nettomutatie in liquide middelen | -886,00K | -44,54% |
Vrije kasstroom | -656,75K | -213,67% |
Over
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
Opgericht
1991
Hoofdvestiging
Website
Werknemers
4
